Prevention of CV events to reduce total mortality & risk of major CV events (CV death, stroke, MI, unstable angina or arterial revascularization) in adults w/ increased risk of ASCVD. Adjunct to diet when response to diet & other non-pharmacological treatments (eg, exercise, wt reduction) is inadequate for primary hypercholesterolemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb); adjunct to diet & other lipid lowering treatments (eg, LDL apheresis) or if such treatments are inappropriate for HoFH; slow or delay progression of atherosclerosis in adults w/ hypercholesterolaemia. Reduction of total cholesterol, LDL & Apo B in childn & adolescents 6-17 yr w/ heterozygous familial hypercholesterolaemia (HeFH).
Statin naive patient or patient switched from another HMG CoA reductase inhibitor Initially 5 or 10 mg once daily. Adjust dose to 20 mg after 2-4 wk, if necessary. Patient w/ severe hypercholesterolaemia at high CV risk (in particular those w/ familial hypercholesterolaemia) who do not achieve treatment goal on 20 mg Double dose to 40 mg daily. HeFHChildn 10-17 yr 5-20 mg once daily, 6-9 yr 5-10 mg once daily.
Sign Out
